Open Access

Prognosis of distal pancreatic cancers controlled by stage

  • Authors:
    • Guopei Luo
    • Kaizhou Jin
    • He Cheng
    • Meng Guo
    • Yitao Gong
    • Zhiyao Fan
    • Chao Yang
    • Qiuyi Huang
    • Quanxing Ni
    • Chen Liu
    • Xianjun Yu
  • View Affiliations

  • Published online on: May 26, 2020     https://doi.org/10.3892/etm.2020.8795
  • Pages: 1091-1097
  • Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with distal (body/tail) pancreatic cancer have been found to present worse outcome than patients with head cancer, which is generally attributed to the great proportion of advanced stages for body/tail cancers upon detection. However, differences in prognosis between head and body/tail pancreatic cancers controlled by stage have not been analyzed in‑depth. In this study, differences in prognosis between head and body/tail pancreatic cancers were examined using the Surveillance, Epidemiology, and End Results Program (SEER) (1973‑2014 registry, 85,715 cases). We found that patients with body/tail pancreatic cancer had worse prognosis than patients with head cancer for all combined stages [adjusted hazard ratio (HR), 1.03, 95% confidence interval (CI), 1.00‑1.05, P=0.025]. Compared with patients with head cancer, patients with body/tail cancer had lower mortality for stage I cancers (HR, 0.85, 95% CI, 0.76‑0.94, P=0.001), no difference in mortality for stages II or III (stage II, HR, 1.00, 95% CI, 0.95‑1.06, P=0.965; stage III, 0.97, 95% CI, 0.91‑1.04, P=0.398), and higher mortality for stage IV (HR, 1.07, 95% CI, 1.04‑1.10, P<0.001). In addition, the proportion of body/tail pancreatic cancer increased from 24.9% in 1973 to 36.3% in 2014. Therefore, tumor location of body/tail is an independent adverse prognostic factor for patients with pancreatic cancer. However, this observation is not applicable when controlled by stage (body/tail versus head pancreatic cancer, better stage I, similar stage II/III, and worse stage IV).
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luo G, Jin K, Cheng H, Guo M, Gong Y, Fan Z, Yang C, Huang Q, Ni Q, Liu C, Liu C, et al: Prognosis of distal pancreatic cancers controlled by stage. Exp Ther Med 20: 1091-1097, 2020.
APA
Luo, G., Jin, K., Cheng, H., Guo, M., Gong, Y., Fan, Z. ... Yu, X. (2020). Prognosis of distal pancreatic cancers controlled by stage. Experimental and Therapeutic Medicine, 20, 1091-1097. https://doi.org/10.3892/etm.2020.8795
MLA
Luo, G., Jin, K., Cheng, H., Guo, M., Gong, Y., Fan, Z., Yang, C., Huang, Q., Ni, Q., Liu, C., Yu, X."Prognosis of distal pancreatic cancers controlled by stage". Experimental and Therapeutic Medicine 20.2 (2020): 1091-1097.
Chicago
Luo, G., Jin, K., Cheng, H., Guo, M., Gong, Y., Fan, Z., Yang, C., Huang, Q., Ni, Q., Liu, C., Yu, X."Prognosis of distal pancreatic cancers controlled by stage". Experimental and Therapeutic Medicine 20, no. 2 (2020): 1091-1097. https://doi.org/10.3892/etm.2020.8795